1984: B.S. In Vitro Cell Biology, State University of New York at Oswego.

1983: Internship, In Vitro Cell Biology, SUNY at Plattsburgh / Alton Jones Science Center.

1982: A.A.S. Medical Laboratory Technology, Trocaire College of Buffalo, NY

1985-86: Industrial internship with Monsanto Agriculture Company

1987-95: Industrial research experience with the Searle Pharmacia Biochemistry Group

Trained in the laboratory of Deserie Collen, Leuven Belgium (animal modeling)

United States Patent number 5,591,431: Enhancement of Clot Lysis.

File date: 03/09/90     Abstract; The invention discloses methods and compositions for increasing clot lysis in the presence of exogenous tissue plasminogen activator (TPA). Inventors; Shasteen, C.S., Day, K.C., Finn, R.F. Assignee:  G.D. Searle and Company, Application number 495008.

  University of Michigan:

Creation of the Rb knockout prostate epithelial cells (Rb-/-PrE)

File date: 10/17/01: Disclosure number 2123

Title: PrERb-/- Mouse Prostate Epithelial Cell Line

Authors:  Day, M.L, Day, K.C. and Hayward, S.W.

Ad Hok Reviewer

Oncogene

Cancer Research

Experimental Cell Research

1995-2006: Research Associate II, Department of Urology, University of Michigan School of Medicine, Ann Arbor, MI

Research projects:

-Directed the establishment of an in vitro model system to study retinoblastoma (pRb) and its role in cell cycle control and carcinogenesis of the prostate.

-Involved in the investigation of E-cadherin with regard to its role in apoptosis, survival and its crucial relations with the Rb/E2F cell cycle control pathway in the adult prostate and mammary glands.

-Current research involves the study of the ADAM-15 protease and its role in carcinogenesis. This research involves collaborations with researchers at the University of MI and researchers at the University in Ulm, Germany.

Laboratory manager:

-Current position also involves the training of Urology residence, research technicians, graduate students and administrative laboratory management duties.

1993-1996: Research Biologist III, Searle Pharmacia, St. Louis, MO

Research projects:

-Research focused on the purification of interleukin receptors and hybrid molecules for the treatment of cancer. Developed feasible affinity chromatography techniques for the purification of these new products.

1988-1993: Research Biologist II, Monsanto Company, St. Louis, MO

Research projects:

-Responsible for the development of animal models to study the

efficacy of potential anticoagulant products. Projects involved the cloning, expression, purification and characterization of TFPI (tissue factor pathway inhibitor) variants.

-Involved in the LTC 4 synthase project (Arachidonic Acid Pathway): Responsible for establishing cell based ELISA assays, demonstrating their application and screening various chemical libraries in search of potential product leads for the treatment of asthma.

1984-1988: Research Biologist I, Monsanto Company, St Louis, MO

Research projects:

-Responsible for the in vivo characterization of the tPA (tissue plasminogen activator) variant proteins created at Monsanto/Searle.

1982- 1984: -Undergraduate Laboratory Teaching Assistant: SUNY Oswego

1981- 1982: -Phlebotomist / Receptionist, Western NY Analytical Labs

RESEARCH EXPERTISE:

Protein expression: Mammalian cell biology / expression - Experienced in transfection of transcient and stable cell lines. Extensive training in primary cell culture systems. Flow cytometry: Currently building a knowledge base for the staining of synchronous and asynchronous epithelial cells for cell cycle determinations and apoptotisis studies. Immunocytochemistry: Experienced in immunohistochemical techniques. Skilled in the production of polyclonal antibodies and immunoassay quantitation techniques including ELISA and Western analysis.

Molecular biology: Extensive experience in RNA/DNA and protein preparation, evaluation and quantitation. Experienced in electrophoresis of DNA/RNA/proteins and northern/western blots analyses. Experience also includes PCR, cloning (vector construction) and diagnostics.

Protein purification: Skilled in the production and purification of recombinant proteins from mammalian cells and refractile body preparations from bacterial cells. Versed in FPLC, HPLC, ion-exchange chromatography and affinity chromotography techniques (ie. antibody, metal and Factor Xa).

in vivo modeling: Developed a number of thromboplastin and endotoxin models in rabbits for the study of anticoagulant proteins.

1. R. Kuefer, K. C. Day, C. G. Kleer, M. S. Sabel, M. D. Hofer, S. Varambally, C. S. Zorn, A. M. Chinnaiyan, M. A. Rubin and Mark L. Day. The ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia. 2006. 8(4): 319-329.

2. Day, K.C., McCabe, M.T., Zhao, X., Wang, YZ., Davis, J.N., Phillips, J., Von Geldern, M., Ried, T., KuKuruga, M.A., Cunha, G.R., Hayward, S.W., and Day, M.L. Homozygous Disruption of the Retinblastoma Gene Alters Cell Cycle and Growth Kinetics but does not Influence Prostatic Differentiation or Morphogenesis. Journal of Biological Chemistry. 2002. 277(46): 44475-44484.

3. Rios-Doria, J., Day, K.C., Kuefer, R., Rashid, M.G. and Day, M.L. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. Journal of Biological Chemistry. 278(2):1372-9. 2003.

4. *C.J. Vallorosi, *K.C. Day, X. Zhao, M. G. Rashid, M. A. Rubin, K. R. Johnson, M. J. Wheelock and M. L. Day. Truncation of the ß-catenin binding domain of E-cadherin precedes epithelial apoptosis during prostate and mammary involution. Journal of Biological Chemistry. 275:3328-3334, 2000 *shared first authorship.

5. M.L. Day, X. Zhao, C.J. Vallorosi, M. Putzi, C.T. Powell, C. Lin and K.C. Day. E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. Journal of Biological Chemistry. 274:9656-9664, 1999.

6. Panvichian, R., Orth, K., Day, M.L., Day, K.C. Yee, C., Kamradt, J., Pilat, M.J. and Pienta K.J.: Signaling Network of Paclitaxel-Induced Apoptosis in the LNCaP Prostate Cancer Cell Line. Urology, 54(4): 746-752,1999.

7. X. Zhao, J.E. Gschwend, C.T. Powell, R.G. Foster, K.C. Day and M.L. Day. Retinoblastoma protein-dependent growth-signal conflict and caspase activity are required for protein kinase C-signaled apoptosis of prostate epithelial cells. Journal of Biological Chemistry. 272:22751-22757, 1997.

8. M.L. Day, R. G. Foster, K.C. Day, X. Zhao, P.A. Humphrey, P. Swanson, A.A. Postigo, S. H. Zhang, and D. C. Dean. Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway. Journal of Biological Chemistry. 272:8125-8128, 1997.

9. Panvichian, R., Orth, K., Day, M.L., Day, K.C. Pilat, M.J. and Pienta, K.J.:  Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Research. 58(20): 4667-4672, 1998.

10. Day, K.C., and Welsch, D.J.  Bacterial Expression, Purification, and Partial Characterization of Amino Acids 94-155 of Human Tissue Factor Pathway Inhibitor (TFPI) as an Inhibitor of Blood Coagulation Factor Xa. Throm. Res. 68, 369-381, 1992.

11. Welsch, D.J., Day, K.C. and Warren, T.G.  Comparison of Recombinant Tissue Factor Pathway Inhibitors Expressed in Human SK Hepatoma, Mouse C127, Baby Hamster Kidney, and Chinese Hamster Ovary Cells. Thromb. and Heam. 68 (1), 54-59, 1992.

12. Wun, T.C., Huang, M.D., Kretzmer, K.K.. Palmier, M.O., Day, K.C., Bullock,J.W., Fok and G.J. Broze:  Immunoaffinity Purification and Characterization of Lipoprotein-Associated Coagulation Inhibitors from Hep G2 Hepatoma, Chang Liver and SK Hepatoma Cells. Journal of Biological Chemistry; 265, 16096-16101, 1990.

13. Day, K.C., Hoffman, L.C., Palmier, M.O., Kretzmer, K.K., Huang, M.D., Pyla, E.Y., Spokas, E., Broze, G.J., Warren, T.G. and Wun, T.C.  Recombinant Lipoprotein-Associated Coagulation Inhibitor Inhibits Tissue Thromboplastin-Induced Intravascular Coagulation in the Rabbit. Blood. 76, 1538-1545, 1990.

14. Haskel, E.J., Torr, S.K., Day, K.C., Palmier, M.O., Wun, T.C., Sobel, B.E and Abendschein, D.R.  Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein- Associated Coagulation Inhibitor (LACI). Circulation, 84, 821-827, 1991.

1. Kuefer R., Day K.C., Kleer C.G., Sabel MS, Hofer M.D., Varambally S, Zorn C., Chinnaiyan A., Rubin M.A. and Day M.L. ADAM15 Disintegrin is Associated with Aggressive Prostate and Breast Cancer Disease. SBUR meeting: Florida; 12/05.

2. KC. Day, M.T. McCabe, X. Zhao, Y. Wang, J. Philips, T. Reid, G.R. Cunha, S.W. Hayward and M.L. Day. Rescue of Embryonic Epithelium Reveals that the Homozygous Deletion of the Retinoblastoma Gene Confers Growth factor Independence and Immortality, but does not Influence Epithelial Differentiation or Tissue Morphogenesis. NDDO Meeting: Amsterdam; 9/02.

3. K.C. Day, M.L. Day, X. Zhao , C.J. Vallorosi, M. Putzi, C.T. Powell, C. Lin. E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. AACR 2002 spring meeting.

4. M.G. Rashid, C.J. Vallorosi, M.G. Sanda, K.C. Day, M.A. Rubin, X. Zhao, J.E. Montie and M.L. Day. Characterization of E-cadherin truncation and its association with the cancerous phenotype in radical prostatectomy specimens. Proceedings of the American Association for Cancer Research. 41:256A, 2000

5. C.J. Vallorosi, K.C. Day, X. Zhao and M.L. Day. Truncation of E-cadherin as a signal for apoptosis during prostate and mammary involution. Proceedings of the American Association for Cancer Research. 40:4765A, 1999

6. KC. Day, X.Zhao and M.L. Day. E-cadherin mediates contact survival of prostate epithelium through the RB cell cycle control pathway: a mechanism for metastasis suppression. American Urologic Association, San Diego , CA . Journal of Urology 159 (5), 1998.

7. KC. Day, X. Zhao, C.T. Powell and M.L. Day. The p21/Rb cell cycle control pathway is required for PKCa-signaled apoptosis of prostate epithelium. Proceedings of the American Association for Cancer Research. 38:4194A, 1997.

8. X. Zhao ,K.C. Day, R.Foster, P.E. Swanson, P.A. Humphrey, D.Dean and M. L. Day. The retinoblastoma gene product mediates apoptosis of prostate epithelium. Society Basic Urol Res Annu Fall Meet. Chapel Hill, NC. December, 1995.

9. Panvichian R, Day KC, Day ML,Pienta KJ. Characterization of Taxol-induced apoptosis in human prostate cancer cells. Proceedings of the American Association for Cancer Research; 38:A1317 1997.

10. Novotny, W.F., Day, K.C., Wun, T.C. and Nieces, G.R. Platelet LACI (TFPI) Is Present in Novel Granules. International Society of Hematology 23rd Congress / The American Society of Hematology 32nd Annual Meeting, Nov. 1990.